File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3978/j.issn.2304-3881.2012.10.04
- Find via
Supplementary
-
Citations:
- Appears in Collections:
Article: Do statins reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis B?
Title | Do statins reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis B? |
---|---|
Authors | |
Issue Date | 2013 |
Publisher | AME Publishing Company. The Journal's web site is located at http://www.thehbsn.org/ |
Citation | Hepatobiliary Surgery and Nutrition, 2013, v. 2 n. 1, p. 34-36 How to Cite? |
Abstract | In subjects with chronic hepatitis B (CHB), the lifetime risk of developing hepatocellular carcinoma (HCC) is estimated to be 25-37 times compared to non-infected subjects. The process of hepatocarcinogenesis is complex and involves well-documented host, viral, and environmental risk factors. The most important risks include host factors such as older age, male gender, the presence of cirrhosis, and viral factors such as the viral load, genotype, and the presence of basal core promoter mutations. To date, antiviral therapy is the only intervention demonstrated to significantly reduce the risk of HCC development in CHB patients. Although oxidative stress has been implicated in cancer development, there is no established benefit shown from treatment with antioxidizing agents such as silymarin, green tea, and vitamin E. |
Persistent Identifier | http://hdl.handle.net/10722/186062 |
ISSN | 2023 Impact Factor: 6.1 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Fung, J | en_US |
dc.contributor.author | Lai, CL | en_US |
dc.contributor.author | Yuen, MF | en_US |
dc.contributor.author | Ng, IOL | en_US |
dc.date.accessioned | 2013-08-20T11:50:26Z | - |
dc.date.available | 2013-08-20T11:50:26Z | - |
dc.date.issued | 2013 | en_US |
dc.identifier.citation | Hepatobiliary Surgery and Nutrition, 2013, v. 2 n. 1, p. 34-36 | en_US |
dc.identifier.issn | 2304-3881 | - |
dc.identifier.uri | http://hdl.handle.net/10722/186062 | - |
dc.description.abstract | In subjects with chronic hepatitis B (CHB), the lifetime risk of developing hepatocellular carcinoma (HCC) is estimated to be 25-37 times compared to non-infected subjects. The process of hepatocarcinogenesis is complex and involves well-documented host, viral, and environmental risk factors. The most important risks include host factors such as older age, male gender, the presence of cirrhosis, and viral factors such as the viral load, genotype, and the presence of basal core promoter mutations. To date, antiviral therapy is the only intervention demonstrated to significantly reduce the risk of HCC development in CHB patients. Although oxidative stress has been implicated in cancer development, there is no established benefit shown from treatment with antioxidizing agents such as silymarin, green tea, and vitamin E. | - |
dc.language | eng | en_US |
dc.publisher | AME Publishing Company. The Journal's web site is located at http://www.thehbsn.org/ | - |
dc.relation.ispartof | Hepatobiliary Surgery and Nutrition | en_US |
dc.title | Do statins reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis B? | en_US |
dc.type | Article | en_US |
dc.identifier.email | Fung, J: jfung@hkucc.hku.hk | en_US |
dc.identifier.email | Lai, CL: hrmelcl@hku.hk | en_US |
dc.identifier.email | Yuen, MF: mfyuen@hku.hk | en_US |
dc.identifier.email | Ng, IOL: iolng@hku.hk | en_US |
dc.identifier.authority | Fung, JYY=rp00518 | en_US |
dc.identifier.authority | Yuen, RMF=rp00479 | en_US |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.3978/j.issn.2304-3881.2012.10.04 | - |
dc.identifier.hkuros | 220779 | en_US |
dc.identifier.volume | 2 | en_US |
dc.identifier.issue | 1 | en_US |
dc.identifier.spage | 34 | en_US |
dc.identifier.epage | 36 | en_US |
dc.publisher.place | Hong Kong | - |
dc.customcontrol.immutable | csl 140226 | - |
dc.identifier.issnl | 2304-3881 | - |